Open Access
Volume 18, Number 2, May 2011
Page(s) 115 - 119
Published online 15 May 2011
  1. Berman J.D. & Lee L.S. Activity of 8-aminoquinolines against Leishmania tropica within human macrophages in vitro. American Journal of Tropical Medicine and Hygiene, 1983, 32, 753–759.
  2. Beveridge E., Goodwin L.G. & Walls L.P. A new series of leishmanicides. Nature, 1958, 182, 316–317. [CrossRef]
  3. Bories C., Cojean S., Huteau F. & Loiseau P.M. Selection and phenotype characterisation of sitamaquine-resistant promastigotes of Leishmania donovani. Biomedicine and Pharmacotherapy, 2008, 62, 164–167. [CrossRef]
  4. Coïmbra E.S., Libong D., Cojean S., Saint-Pierre-Chazalet M., Solgadi A., Le Moyec L., Duenas-Romero A.M., Chaminade P. & Loiseau P.M. Mechanism of interaction of sitamaquine with Leishmania donovani. The Journal of Antimicrobial Chemotherapy, 2010, 65, 2548–2555. [CrossRef] [PubMed]
  5. Desjeux P. Leishmaniasis: current situation and new perspectives. Comparative Immunology, Microbiology and Infectious Diseases, 2004, 27, 305–318. [CrossRef] [PubMed]
  6. Dietze R., Carvalho S.F.G., Valli L.C., Berman J., Brewer T., Milhous W., Sanchez J., Schuster B. & Grogl M. Phase II trial of WR6026, an orally administrated 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. American Journal of Tropical Medicine and Hygiene, 2001, 65, 685–689.
  7. Dueñas-Romero A.M., Loiseau P.M. & Saint-Pierre-Chazalet M. Interaction of sitamaquine with membrane lipids of Leishmania donovani promastigotes. Biochimica et Biophysica Acta, 2007, 1768, 246–252. [CrossRef] [PubMed]
  8. Elderfield R.C., Mertel H.E., Mitch R.T., Wempen I.M. & Werble E.J.. Synthesis of primaquine and certain of its analogs. Journal of the American Chemical Society, 1955, 77, 4816–4819. [CrossRef]
  9. Garnier T., Brown M.B., Lawrence M.J. & Croft S.L. In vitro and in vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis. Journal of Pharmacy and Pharmacology, 2006, 58, 1043–1054. [CrossRef]
  10. Jha T.K., Sundar S., Thakur C.P., Bachmann P., Karbwang J., Fischer C., Voss A. & Berman J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. New England Journal of Medicine, 1999, 341, 1795–800. [CrossRef]
  11. Jha T.K., Sundar S., Thakur C.P., Felton J.M., Sabin A.J. & Horton J. A phase II dose-ranging study of sitamaquine for treatment of visceral leishmaniasis in India. American Journal of Tropical Medicine and Hygiene, 2005, 73, 1005–1011.
  12. Kinnamon K.E., Steck E.A., Loizeaux P.S., Hanson W.L., Chapman W.L. Jr. & Waits V.B. The antileishmanial activity of lepidines. American Journal of Tropical Medicine and Hygiene,, 1978, 27, 751–757.
  13. Langreth S.G., Berman J.D., Riordan G.P. & Lee L.S. Finestructure alterations in Leishmania tropica within macrophages exposed to antileishmanial drugs in vitro. Journal of Protozoology, 1983, 30, 555–561.
  14. López-Martín C., Pérez-Victoria J.M., Carvalho L., Castanys S. & Gamarro F. Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocalcisomes. Antimicrobial Agents and Chemotherapy, 2008, 52, 4030–4036. [CrossRef] [PubMed]
  15. Muschiol C., Berger M.R., Schuler B., Scherf H.R., Garzon F.T., Zeller W.J., Unger C., Eibl H.J. & Schmähl D. Alkyl phosphocholines: toxicity and anticancer properties. Lipids, 1987, 22, 930–934. [CrossRef] [PubMed]
  16. Sherwood J.A., Gachihi G.S., Muigai R.K., Skillman D.R., Mugo M., Rashid J.R., Wasunna K.M., Were J.B., Kasili S.K. & Mbugua J.M. et al. Phase II efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clinical Infectious Diseases, 1994, 19, 1034–1039. [CrossRef]
  17. Sindermann H. & Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, 100(Suppl 1), S17–S20. [CrossRef] [PubMed]
  18. Soto J., Arana B.A., Toledo J., Rizzo N., Vega J.C., Diaz A., Luz M., Gutierrez P., Arboleda M., Berman J.D., Junge K., Engel J. & Sindermann H. Miltefosine for new world cutaneous leishmaniasis. Clinical Infectious Diseases, 2004, 38, 1266–1272. [CrossRef]
  19. Soto J. & Berman J. Treatment of New World cutaneous leishmaniasis with miltefosine. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, 100(Suppl 1), S34–S40. [CrossRef] [PubMed]
  20. Soto J. & Toledo J.T. Oral miltefosine to treat new world cutaneous leishmaniasis. Lancet Infectious Diseases, 2007, 7, 7. [CrossRef]
  21. Sundar S., Jha T.K., Thakur C.P., Engel J., Sindermann H., Fischer C., Junge K., Bryceson A. & Berman J. Oral miltefosine for Indian visceral leishmaniasis. New England Journal of Medicine, 2002, 347, 1739–1746. [CrossRef]
  22. Sundar S., Rai M., Chakravarty J., Agarwal D., Agrawal N., Vaillant M., Olliaro P. & Murray H.W. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clinical Infectious Diseases, 2008, 47, 1000–1006. [CrossRef]
  23. Theoharides A.D., Chung H., Velazquez H. Metabolism of a potential 8-aminoquinoline antileishmanial drug in rat liver microsomes. Biochemical Pharmacology, 1985, 34, 181–188. [CrossRef] [PubMed]
  24. Theoharides A.D., Kim M.M., Ashmore R.W. & Shipley L.A. Identification and quantification of human urinary metabolites of a candidate 8-aminoquinoline antileishmanial drug WR-6026. Proceedings of American Society of Experimental Biology, 1987, 46, 865.
  25. Vercesi A. & Docampo R. Ca2+ transport by digitonin-permeabilized Leishmania donovani. Effects of Ca2+, pentamidine and WR-6026 on mitochondrial membrane potential in situ. Biochemical Journal, 1992, 284, 463–467.
  26. Vercesi A., Rodrigues C., Castisti R. & Docampo R. Presence of a Na(+)/H(+) exchanger in acidocalcisomes of Leishmania donovani and their alkalization by anti-leishmanial drugs. FEBS Letters, 2000, 473, 203–206. [CrossRef] [PubMed]
  27. Wasunna M.K., Rhashid J.R., Mbui J., Kirigi G., Kinoti D., Lodenyo H., Felton J.M., Sabin A.J. & Horton J. A phase II dose-increasing study of sitamaquine for treatment of visceral leishmaniasis in Kenya. American Journal of Tropical Medicine and Hygiene, 2005, 73, 871–876.
  28. World Health Organization. Leishmaniasis Disease Burden. Available from:, 2010.
  29. Yeates C. Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). Current Opinion in Investigational Drugs, 2002, 3, 1446–1452.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.